Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B

European Journal of Dermatology

Volumn 15, Issue 2, 2005, Pages 107-109

  Ketikoglou, Ioannis ^a   Karatapanis, Stelios ^a   Elefsiniotis, Ioannis ^a   Kafiri, Georgia ^a   Moulakakis, Antonios ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Hepatitis B; Interferon; Pegylated interferon; Psoriasis

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2B; VIRUS DNA;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CHRONIC HEPATITIS; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INJECTION SITE; LIVER BIOPSY; MALE; PRURITUS; PSORIASIS; RASH; SKIN BIOPSY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; PSORIASIS;

EID: 15944400023     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68(5): 556-67.
2. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40(7): 539-51.
3. Ishok K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
4. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003; 39: S93-S98.
5. Okanoue T, Itoh Y, Yasui K. Autoimmune disorders in interferon therapy. Nippon Rinsha 1994; 52(7): 1924-8.
6. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis. C Gastroenterology 1995; 108: 1770-7.
7. Mayet WJ, Hess G, Gerken G, et al. Treatment af chronic type -B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989; 10: 24-8.
8. Paquet P, Pierard-Franchimont C, Arrese JE, et al. Cutaneous side effects of interferons. Rev Med Liege 2001; 56(10): 699-702.
9. Shiftman ML. Pegylated interferans: what role will they play in the treatment of chronic hepatitis C? Curr Gastroenterol Rep 2001; 3(1): 30-7.
10. Bassis D, Charron A, Rouzier-Panis R, et al. Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alpha in an HIV-infected patient. Eur J Dermatol 2002; 12(1): 99-102.
11. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Cl Invest 2004; 113: 1664-75.
12. Gudjonsson JE, Johnston A, Sigmunddottir H, Valdimarsson H. Immuno-pathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135(1): 1-8.
13. Rompruk AV, Romphruk A, Choonhakarn C, Puapairoj C, Inolo H, Leelayuwat C. Major histocompatibility complex class I chain-related gene A in Thoi psoriasis patients/MICA association as a part of human leucocyte antigen B-Cw haplotypes. Tissue antigens; (6): 547-554.
14. Bowcock AM, Cookson WO. The genetics of psoriasis, proriatic arthritis and atopic dermatitis. Hum Mol Genet 2004; 13(Spec No 1): R43-R55.
15. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet 1986; 1(8496): 1466-8.
16. Hartmann F, Von Wussow P, Deicher H. Exacerbation of psoriasis during alpha-interferon therapy. Dtsch Med Wochenschr 1989; 114(3): 96-8.
17. Garcia-Lora E, Tercedor J, Massare E, et al. Interferon induced psoriasis in a patient with chronic hepatitis C. Dermatology 1993; 187: 280.
18. Georgetson MJ, Yarze JC, Lalos AT, et al. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol 1993; 88(10): 1756-8.
19. Downs AM, Dunnill MG. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 2000; 25(4): 351-2.
20. Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon-alpha. Postgrad Med J 2000; 76: 365-6.
21. Funk J, Langeland T, Schrumpf E, et al. Psoriasis induced by interferon-alpha. Br J Dermatol 1991; 125(5): 463-5.